Danaher FY2025 EPS Forecast Increased by Leerink Partnrs

Danaher Co. (NYSE:DHR) – Analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Danaher in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the conglomerate will post earnings of $8.26 per share for the year, up from their prior forecast of $8.22. The consensus estimate for Danaher’s current full-year earnings is $7.50 per share. Leerink Partnrs also issued estimates for Danaher’s Q4 2025 earnings at $2.50 EPS and FY2026 earnings at $9.26 EPS.

Several other research firms have also recently weighed in on DHR. Stephens restated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Raymond James dropped their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research report on Tuesday. Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Guggenheim assumed coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Finally, Barclays decreased their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Stock Up 0.0 %

DHR opened at $244.19 on Thursday. The firm has a market capitalization of $176.38 billion, a P/E ratio of 46.60, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher has a one year low of $225.42 and a one year high of $281.70. The company has a fifty day moving average price of $234.90 and a 200-day moving average price of $253.47. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the company earned $2.02 earnings per share. Danaher’s revenue for the quarter was up 3.1% on a year-over-year basis.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DHR. Decker Retirement Planning Inc. purchased a new position in shares of Danaher during the fourth quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher during the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter worth $50,000. Finally, Darwin Wealth Management LLC acquired a new position in Danaher during the third quarter valued at $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.